Life Sciences companies face difficulties incorporating ESG into their compliance programs
Hogan Lovells released a survey that tracked the thinking of compliance professionals who are implementing ESG into compliance programs.
ESG (environmental, social and governance) has become a top compliance concern for life sciences companies around the world—yet the evidence suggests that many are struggling to embed ESG into their existing compliance programs.
A survey of compliance professionals at 100 multinational life sciences companies globally reveals an overwhelming majority—84%—report that ESG risk is increasing as a priority for their board. Yet more than four in five also report that the failure to embed ESG into existing risk practices is impeding their organization’s ESG risk management.
Hogan Lovells’ Navigating Deep Waters survey, released today, tracks the thinking of experienced compliance professionals who are integrating the social and governance aspects of ESG into existing compliance programs.
Read more about Hogan Lovell's survey here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
